Results 51 to 60 of about 218,137 (295)
Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids
Journal of Equine Veterinary Science, 2021 The aim of the study was to assess the expression of the immune checkpoint inhibitor programmed death-ligand 1 (PD-L1) in equine sarcoids (ES). Programmed death-ligand 1 is expressed by various cancer cells to block T cell-mediated elimination of tumor cells.
Jennifer Benvegnen +4 more
openaire +2 more sources
Cells, 2022 Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej +8 more
doaj +1 more source
Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]
, 2012 For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor +6 more
core +3 more sources
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Zhongguo aizheng zazhi, 2021 Background and purpose: Programmed death 1 (PD-1) plays an important role in the regulation of peripheral immune tolerance. The expression of PD-1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma (HCC) and the relationship between PD-1 ...
肖 锋 +4 more
doaj
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]
, 2016 Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan +21 more
core +2 more sources
Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer [PDF]
Journal of Oncology Practice, 2016 Programmeddeath 1 (PD-1)/programmed death ligand 1 (PD-L1) engagement is a physiologic process that inhibits the overactivation of T cells and thus serves to maintain self-tolerance and prevent autoimmunity. This mechanism is frequently hijacked by tumor cells, including lymphoma, when they aberrantly express PD-L1 (and PD-L2) proteins; however, this ...
openaire +2 more sources
FEBS Letters, EarlyView.Mitochondrial remodeling shapes neural and glial lineage progression by matching metabolic supply with demand. Elevated OXPHOS supports differentiation and myelin formation, while myelin compaction lowers mitochondrial dependence, revealing mitochondria as key drivers of developmental energy adaptation.
Sahitya Ranjan Biswas +3 more
wiley +1 more source
Tzu Chi Medical Journal, 2023 Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj +1 more source
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]
, 2018 Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim +5 more
core +1 more source